C2T-admin

/C2T-admin

About C2T-admin

This author has not yet filled in any details.
So far C2T-admin has created 14 blog entries.

PENTAX Medical Expands Interventional Endoscopy Offering with Acquisition of C2 Therapeutics

2018-05-30T19:48:05+00:00

Press Release (U.S.A. version) – Outside U. S. A. version follows after U. S. A. version

Montvale, NJ – January 9, 2017 – PENTAX Medical, a division of the HOYA Group, Tokyo, Japan announced today that they have acquired C2 Therapeutics, Redwood City, CA for an undisclosed amount. C2 Therapeutics develops the C2 CryoBalloon™ Ablation System for the endoscopic ablation of unwanted tissue such as Barrett’s esophagus1. This acquisition will help strengthen the company’s therapeutic endoscopy portfolio.

Click here to see full release.

PENTAX Medical Expands Interventional Endoscopy Offering with Acquisition of C2 Therapeutics 2018-05-30T19:48:05+00:00

C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus

2018-05-30T19:48:05+00:00

REDWOOD CITY, Calif. – June 7, 2016 – C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system in patients with Barrett’s esophagus.

Click here to see full release.

C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus 2018-05-30T19:48:05+00:00

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System

2018-05-30T19:48:05+00:00

REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016, which is taking place May 21 – 24 in San Diego.

Click here to see full release.

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System 2018-05-30T19:48:05+00:00

CE Mark Granted for Novel Cryoablation Device Aimed at Reducing the Incidence of Esophageal Cancer

2018-05-30T19:48:05+00:00

Redwood City, Calif. – October 22, 2015 – C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced that it received the CE (Conformité Européenne) mark for its Coldplay CryoBalloon® Focal Ablation System. The product is now available for commercial use initially in parts of Western Europe. Cryoablation is a process that uses extreme cold to precisely destroy or damage diseased tissue while minimizing damage to surrounding healthy tissue.

Click here to see full release.

CE Mark Granted for Novel Cryoablation Device Aimed at Reducing the Incidence of Esophageal Cancer 2018-05-30T19:48:05+00:00

C2 Therapeutics receives 510(k)

2018-05-30T19:48:05+00:00

Redwood City, Calif.July 29, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced US Food and Drug Administration (FDA) 510(k) clearance for the Coldplay Cryoballoon™ Full Ablation System and the Coldplay Cryoballoon™ Swipe Ablation System.

“The clearance of Coldplay Cryoballoon Full and Swipe Systems is an important milestone in broadening the company’s portfolio,” said Peter Garcia-Meza, President and CEO of C2 Therapeutics. “The Full and Swipe Ablation Systems will be critical in allowing physicians to ablate larger areas of tissue in endoscopic applications.”

Click here to see full release.

C2 Therapeutics receives 510(k) 2018-05-30T19:48:05+00:00

Successful Safety and Dosing Results Published

2018-05-30T19:48:05+00:00

Redwood City, Calif.July 20, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced the publication of excellent safety and dosing data related to the company’s Coldplay Cryoballoon™ Focal Ablation System.  Results from the prospective, non-randomized study titled, “Treatment of Barrett’s Esophagus with a novel focal cryoablation device: a safety and feasibility study” were published in the latest edition of the scientific journal Endoscopy.

Click here to see full release.

Successful Safety and Dosing Results Published 2018-05-30T19:48:05+00:00

Two Clinical Studies to be Presented at DDW 2014

2018-05-30T19:48:05+00:00

Redwood City, Calif. – May 2, 2014 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced that data from two clinical studies evaluating the therapeutic impact of its Coldplay Cryoballoon Focal Ablation System will be presented at Digestive Disease Week® (DDW®), on May 6th in Chicago, IL.

C2 Therapeutics DDW 2014 Clinical Study Announcement Card.

Click here for full press release.

Two Clinical Studies to be Presented at DDW 2014 2018-05-30T19:48:05+00:00

C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation

2018-05-30T19:48:05+00:00

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced excellent interim results for its Coldplay Cryoballoon Focal Ablation System at the Digestive Disease Week (DDW) in Chicago. Data from the study titled, “Clinical evaluation of a new CryoBalloon Focal Ablation System for the elimination of Barrett’s esophagus” were presented in a poster session today by Bas Weusten, MD, Professor of Innovative Gastrointestinal Endoscopy Senior Gastroenterologist, St. Antonius Hospital Nieuwegein, The Netherlands, and trial’s Principal Investigator.

Click here for full release.

C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation 2018-05-30T19:48:05+00:00

C2 Therapeutics Receives FDA Clearance

2018-05-30T19:48:05+00:00

C2 Therapeutics’ Receives FDA Clearance for Next Generation Cryoballoon Ablation System

Redwood City, Calif. – August 22, 2013 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus), today announced that it received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Cryoballoon Focal Ablation System.  This is the company’s second 510(k) clearance and will be working to introduce Cryoballoon ablation in the United States.  nitial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation …

Click here to see full release.

C2 Therapeutics Receives FDA Clearance 2018-05-30T19:48:05+00:00

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment

2018-05-30T19:48:05+00:00

West Penn Allegheny Health System researchers are investigating whether a new ablation technology can provide safer and more effective treatment for patients with Barrett’s Esophagus, a condition associated with gastroesophageal reflux disease (GERD) that can progress to esophageal cancer if left untreated.

Click here for the full story.

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment 2018-05-30T19:48:05+00:00